ARS PHARMACEUTICALS CLASS ACTION LAWSUIT: A COMPLETE INVESTOR GUIDE [2026]
Key Details of the ARS Pharmaceuticals Class Action Lawsuit (2026)
ARS Pharmaceuticals Class Action: A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026. The action follows a 23.9% stock drop triggered by the company’s disclosure that it missed expected CVS Caremark formulary coverage timelines for its neffy nasal spray.
Lawsuit Background
- The Trigger: On June 24, 2026, ARS announced that CVS Caremark delayed its decision on expanded insurance coverage for neffy until January 2027, missing the anticipated July 1 window.
- The Allegations: The ARS Pharmaceuticals Class Action alleges that ARS made false or misleading statements regarding the timeline and certainty of securing broad commercial payer coverage and removing prior authorizations ahead of peak summer/back-to-school allergy seasons.
- Stock Impact: Following the disclosure, ARS stock dropped from $10.54 to $8.02 per share on June 25, 2026.
Key Deadlines and Details
- Lead Plaintiff Deadline: October 5, 2026, is the court deadline for investors to file a motion to serve as the lead plaintiff.
- Eligibility: Shareholders who suffered financial losses during the March 9 – June 24, 2026 class period may qualify to participate.
If you purchased or otherwise acquired EquipmentShare shares during this time and suffered financial losses, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling (855) 846-6529 or via e-mail at [email protected]. (24/7/365).
How to Get Involved in the ARS Pharmaceuticals Class Action Lawsuit
- If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.
- You may be notified of a class action by mail if you are an eligible class member.
- You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.
- If you believe you may have a claim, you can contact a securities class action law firm for guidance. Contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. (24/7/365).
What Is a Notice in a Class Action
- A notice in a class action like the ARS Pharmaceuticals class action lawsuit refers to the formal communication sent to potential class members informing them about the lawsuit and their rights to participate in it.
- This notice is a crucial part of the class action process as it ensures that all individuals who may be affected by the outcome of the ARS Pharmaceuticals class action lawsuit are aware of their rights and can choose whether to opt-in or opt-out of the class.
- The notice typically contains information about the nature of the ARS Pharmaceuticals class action lawsuit, the claims being made, and the potential benefits or risks associated with participation. It also provides instructions on how to file a claim or request exclusion from the class.
- Overall, the notice serves to promote transparency and fairness in the class action process by ensuring that all affected individuals have an opportunity to exercise their legal rights.
Allegations in the ARS Pharmaceuticals Class Action Lawsuit
ARS Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for severe allergic reactions. ARS Pharmaceuticals is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
The ARS Pharmaceuticals class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Defendants knew or recklessly disregarded potential timeline issues with CVS Caremark’s formulary addition and coverage decision related to neffy;
- The guidance ARS Pharmaceuticals provided to investors related to the timeline for expansion of insurance coverage for neffy with CVS Caremark may be significantly shifted, impacting commercialization efforts; and
- The expanded insurance coverage may not be available by the July 1 deadline, thus, ARS Pharmaceuticals would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.
On June 24, 2026, after the market closed, ARS Pharmaceuticals published a press release allegedly announcing that ARS Pharmaceuticals did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS Pharmaceuticals did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS Pharmaceuticals allegedly also stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027.
On this news, the price of ARS Pharmaceuticals stock declined nearly 24%, according to the ARS Pharmaceuticals class action lawsuit.
.
Rights of Investors in the ARS Pharmaceuticals Class Action Lawsuit
Investors affected by the ARS Pharmaceuticals class action lawsuit possess specific rights that they can exercise. Understanding these rights is vital for anyone considering involvement in the ARS Pharmaceuticals class action lawsuit.
Right to Information in the ARS Pharmaceuticals class action lawsuit
- Investors have the right to receive accurate and timely updates regarding theARS Pharmaceuticals class action lawsuit.
- This includes information on the case’s progress, potential settlements, and any necessary actions they may need to undertake.
Right to Participate in the ARS Pharmaceuticals class action lawsuit
- Affected investors have the right to join the ARS Pharmaceuticalsclass action lawsuit.
- This allows them to collaborate with other investors in seeking compensation for their losses without the burden of filing individual lawsuits.
Right to Legal Representation in the ARS Pharmaceuticals class action lawsuit
- Investors can seek legal counsel to navigate the complexities of the ARS Pharmaceuticals class action lawsuit.
- Legal professionals can provide guidance and support throughout the process.
- If you suffered substantial losses and wish to serve as lead plaintiff of the ARS Pharmaceuticals class action lawsuit or just have general questions about your rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
Contingency Fee Agreements: No Cost to Hire a Lawyer
- No Fee: It does not cost anything to hire a lawyer if you are eligible for an ARS Pharmaceuticals class action lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
- Talk with a Lawyer Free of Charge: A lawyer can explain the process of an ARS Pharmaceuticals class action lawsuit and answer any questions you may have free of charge.
Contact Timothy L. Miles Today About a ARS Pharmaceuticals Class Action Lawsuit
The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the ARS Pharmaceuticals class action lawsuit, or just have general questions about your rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling (855) 846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube
Class Actions Securities Fraud Directory
Explore our securities fraud resources and active class action cases.